Get started
LivaNova PLCLivaNova PLCLivaNova PLC

LivaNova PLC

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options Bonds

LIVN trade ideas

LIVN - BULLISH PERFORMANCE LEADS TO BULLISH OUTLOOKGood Morning Everyone, Hope all is well. LIVN with increased volume and momentum over positive future company growth outlook. As you can see strong break into a new price cycle. The goal would be to enter at the current price point or for less risk enter of the breakout and confirmed support. There are 3 zones in play. You can hold to which ever depending on your comfort level and risk assessment. Breakeven win rates ZONE 1 - 49.80% ZONE 2 - 48.82% ZONE 3 - 47.65% Total gain at ZONE 3 14% Good Luck!
NASDAQ:LIVNLong
by mindfullylost
Bull Flag Multiple BottomsLooks like a bull flag (o: Lots of bottoms on this one.. No rising wedges in yearly chart.. Earnings estimated 2-24 and they do miss )o: Short interest 6.6% depending on where you look..Looks like this one can be volatile if it feels like it (o: Not a recommendation.. Long term high is 131.54 LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV") and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, treatment-resistant depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. LivaNova PLC has a research collaboration with Verily to gain insights into Vagus nerve stimulation impact on difficult-to-treat depression. The company was founded in 1987 and is headquartered in London, the United Kingdom.
NASDAQ:LIVNLong
by lauralea